SCHEMBL14896913

SCHEMBL14896913

O=C(Nc1ccccn1)c1cnc2ccc(N3CC(F)(F)C3)nn12

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 3/20 0.43
▸ NPC1 O15118 6/20 0.40
▸ RAB9A P51151 6/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MITF O75030 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ NTRK1 P04629 3/20 0.37
▸ GRM5 P41594 2/20 0.37
▸ PTPN11 Q06124 1/20 0.37
▸ NTRK3 Q16288 2/20 0.37
▸ NTRK2 Q16620 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14896715 0.92 IRAK4 (0.43) IRAK4NPC1RAB9AKMT2ANTRK1
SCHEMBL20355594 0.91 IRAK4 (0.44) IRAK4NPC1RAB9AKMT2AMEN1
SCHEMBL14897306 0.90 IRAK4 (0.46) IRAK4NPC1RAB9AKMT2AMEN1
SCHEMBL14897606 0.88 IRAK4 (0.42) IRAK4NTRK1
SCHEMBL16193154 0.88 IRAK4 (0.43) IRAK4NPC1RAB9AKMT2AKDM4E
SCHEMBL16193069 0.87 IRAK4 (0.42) IRAK4NTRK1
SCHEMBL14897349 0.86 IRAK4 (0.44) IRAK4KDM4ENTRK1GRM5
SCHEMBL14897190 0.86 PTPN11 (0.46) IRAK4NPC1RAB9AKMT2ANTRK1
SCHEMBL14897543 0.83 IRAK4 (0.49) IRAK4NPC1RAB9AKMT2AKDM4E
SCHEMBL14897039 0.83 IRAK4 (0.47) IRAK4NPC1RAB9AKDM4ENTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885NPC1 3941/4885RAB9A 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback